Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,236Revenue $M135Net Margin (%)-23.9Altman Z-Score3.1
Enterprise Value $M1,178EPS $-0.3Operating Margin %-20.3Piotroski F-Score4
P/E(ttm)--Beneish M-Score0.2Pre-tax Margin (%)-23.9Higher ROA y-yY
Price/Book28.510-y EBITDA Growth Rate %1.4Quick Ratio2.6Cash flow > EarningsN
Price/Sales9.15-y EBITDA Growth Rate %-4.8Current Ratio2.8Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-19.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-79.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M129ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with HALO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HALOFirst Eagle Investment 2015-12-31 Add0.01%$12.93 - $18.59
($16.02)
$ 9.90-38%Add 6.10%4,305,900
HALOJoel Greenblatt 2015-12-31 Sold Out $12.93 - $18.59
($16.02)
$ 9.90-38%Sold Out0
HALOFirst Eagle Investment 2015-09-30 Reduce-0.01%$13.25 - $24.75
($20.12)
$ 9.90-51%Reduce -2.49%4,058,500
HALOJoel Greenblatt 2015-09-30 Reduce$13.25 - $24.75
($20.12)
$ 9.90-51%Reduce -21.11%28,955
HALOKen Fisher 2015-09-30 Reduce$13.25 - $24.75
($20.12)
$ 9.90-51%Reduce -4.48%707,780
HALOFirst Eagle Investment 2015-06-30 Add0.02%$14.28 - $22.58
($17.52)
$ 9.90-43%Add 8.55%4,162,000
HALOJoel Greenblatt 2015-06-30 Buy 0.01%$14.28 - $22.58
($17.52)
$ 9.90-43%New holding36,701
HALOKen Fisher 2015-06-30 Reduce$14.28 - $22.58
($17.52)
$ 9.90-43%Reduce -2.86%740,955
HALOFirst Eagle Investment 2015-03-31 Reduce$9.82 - $16.2
($14.42)
$ 9.90-31%Reduce -3.92%3,834,050
HALOFirst Eagle Investment 2014-09-30 Add0.02%$8.67 - $10.2
($9.52)
$ 9.904%Add 30.25%3,640,480
HALOFirst Eagle Investment 2014-06-30 Add0.03%$7.09 - $12.31
($8.46)
$ 9.9017%Add 94.94%2,795,080
HALOKen Fisher 2014-06-30 Buy 0.02%$7.09 - $12.31
($8.46)
$ 9.9017%New holding791,760
HALOFirst Eagle Investment 2013-12-31 Buy 0.05%$9.66 - $15.7
($12.86)
$ 9.90-23%New holding1,294,580
HALOGeorge Soros 2011-12-31 Sold Out -0.0018%$5.72 - $9.73
($8.21)
$ 9.9021%Sold Out0
HALOGeorge Soros 2011-09-30 Buy $5.62 - $7.29
($6.61)
$ 9.9050%New holding17,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HALO is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


HALO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Stelzer LaurieCFO 2015-08-20Buy10,000$17.24-42.58view
Stelzer LaurieCFO 2015-08-20Buy10,000$17.24-42.58view
Kelley Kenneth JDirector 2015-06-18Sell20,000$21-52.86view
Kelley Kenneth JDirector 2015-03-05Sell40,000$15.33-35.42view
RAMSAY DAVID AVP and CFO 2014-09-16Buy25,000$8.911.24view
Torley HelenPresident and CEO 2014-09-16Buy50,000$8.9210.99view
PATTON JOHN STUARTDirector 2014-08-19Sell75,000$9.96-0.6view
Engler RobertDirector 2014-08-14Sell35,000$9.96-0.6view
Engler RobertDirector 2014-05-15Sell126,700$7.5630.95view
PATTON JOHN STUARTDirector 2013-09-16Sell75,000$9.138.43view

Quarterly/Annual Reports about HALO:

News about HALO:

Articles On GuruFocus.com
First Eagle Overseas Fund Q2 Commentary Aug 03 2015 
Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) May 07 2010 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Nov 06 2009 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : May... May 05 2016
Halozyme to Host First Quarter 2016 Financial Results Conference Call Apr 20 2016
Halozyme to Host First Quarter 2016 Financial Results Conference Call Apr 20 2016
Halozyme Expands Oncology Pipeline With Two Compounds Designed For Activity In The Tumor... Apr 18 2016
Halozyme Expands Oncology Pipeline With Two Compounds Designed For Activity In The Tumor... Apr 18 2016
Halozyme Therapeutics, Inc. – Value Analysis (NASDAQ:HALO) : March 23, 2016 Mar 23 2016
Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : March... Mar 22 2016
ETF’s with exposure to Halozyme Therapeutics, Inc. : March 21, 2016 Mar 21 2016
Halozyme To Present Data From Five Preclinical Studies At American Association Of Cancer Research... Mar 17 2016
Halozyme Doses First Patient In Phase 3 Clinical Trial Of PEGPH20 In Combination With ABRAXANE® And... Mar 16 2016
ETF’s with exposure to Halozyme Therapeutics, Inc. : March 10, 2016 Mar 10 2016
HALOZYME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers Mar 07 2016
Halozyme Appoints Jim Daly To Board Of Directors Mar 07 2016
3 Top Biopharma Movers of the Past Week Mar 06 2016
HALOZYME THERAPEUTICS INC Financials Mar 05 2016
Halozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q4, 2015 By the Numbers Mar 03 2016
Halozyme Therapeutics To Present At Upcoming Healthcare Conferences Mar 02 2016
Edited Transcript of HALO earnings conference call or presentation 29-Feb-16 9:30pm GMT Mar 01 2016
Halozyme Therapeutics beats 4Q profit forecasts Feb 29 2016
Halozyme Therapeutics beats 4Q profit forecasts Feb 29 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)